Editorial
Imiquimod
Abstract
In this issue of the Southern Medical Journal, Yuchi Chang and Stephen Tyring present an interesting review of the dermatologic product imiquimod (Aldara, 3M Pharmaceuticals) in their article “Current and Potential Uses of Imiquimod”. Although approved by the United States Food and Drug Administration since 1997 as a topical treatment for genital and perianal warts, investigators have found this compound may offer an alternative treatment for a wide variety of medical conditions.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
